Legend Biotech says it will take a “smart approach” to Carvykti’s routine manufacturing maintenance after rival Bristol Myers Squibb warned of sales disruption for its BCMA CAR-T, Abecma. For its second quarter 2023, Bristol Myers Squibb reported worldwide sales for its B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy Abecma (ide-cel) of $132 million, up 48% year-on-year. However, during its financial call, the company warned stakeholders the upwards trajectory of the therapy seen since its…